Corporate R&D investment in 2008: a global increase with EU companies leading USA and Japan; Pharma/biotech top sectors

16 November 2009

Worldwide corporate R&D investment increased by 6.9% in 2008, in spite of the economic crisis, according to the 2009 "European Union Industrial R&D Investment Scoreboard" released today on the European Commission's web site.

With an 8.1% increase, the R&D investment growth of EU companies, defined as those having headquarters within the EU, is significantly higher than US ones for the second year, at 5.7%, and Japanese firms, at 4.4%. Two EU companies feature in the top 10: Volkswagen in the third place with an R&D investment of 5.93 billion euros ($8.8 billion) and Nokia in the eighth. The world's biggest investor in R&D was Toyota Motor, with 7.61 billion. euros The report also shows that companies from emerging countries have the highest R&D investment growth.

"It is good news that EU companies kept up their R&D investment against the background of the economic crisis in 2008. This is the best strategy to emerge stronger out of the crisis. We must support EU companies' efforts and provide incentives to reinforce the EU research intensive sectors. Building a truly European research area is part of the answer, together with EU actions to promote smart investments in R&D. I also welcome the increase of R&D investment by EU companies active on low carbon energy technologies. They represent new sources of EU growth and jobs," said European Science and Research Commissioner Janez Potocnik.

Sector trends

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Biotechnology